IL153494A0 - Particulate composition of eletriptan showing a sigmoidal pattern of controlled release - Google Patents

Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Info

Publication number
IL153494A0
IL153494A0 IL15349401A IL15349401A IL153494A0 IL 153494 A0 IL153494 A0 IL 153494A0 IL 15349401 A IL15349401 A IL 15349401A IL 15349401 A IL15349401 A IL 15349401A IL 153494 A0 IL153494 A0 IL 153494A0
Authority
IL
Israel
Prior art keywords
eletriptan
showing
controlled release
particulate composition
sigmoidal pattern
Prior art date
Application number
IL15349401A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL153494A0 publication Critical patent/IL153494A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electroluminescent Light Sources (AREA)
  • Luminescent Compositions (AREA)
IL15349401A 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release IL153494A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition
PCT/IB2001/001279 WO2002009675A1 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Publications (1)

Publication Number Publication Date
IL153494A0 true IL153494A0 (en) 2003-07-06

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15349401A IL153494A0 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Country Status (39)

Country Link
US (1) US20020034545A1 (cs)
EP (1) EP1365748B1 (cs)
JP (1) JP2004505034A (cs)
KR (1) KR20030024820A (cs)
CN (1) CN1630511A (cs)
AP (1) AP2001002233A0 (cs)
AR (1) AR030099A1 (cs)
AT (1) ATE308978T1 (cs)
AU (1) AU2001270932A1 (cs)
BG (1) BG107361A (cs)
BR (1) BR0112839A (cs)
CA (1) CA2417887C (cs)
CZ (1) CZ2003241A3 (cs)
DE (1) DE60114887T2 (cs)
EA (1) EA200300110A1 (cs)
EC (1) ECSP034451A (cs)
EE (1) EE200300051A (cs)
ES (1) ES2250429T3 (cs)
GB (1) GB0018968D0 (cs)
GT (1) GT200100149A (cs)
HR (1) HRP20030036A2 (cs)
HU (1) HUP0301453A2 (cs)
IL (1) IL153494A0 (cs)
IS (1) IS6649A (cs)
MA (1) MA26934A1 (cs)
MX (1) MXPA03000999A (cs)
NO (1) NO20030498D0 (cs)
NZ (1) NZ522976A (cs)
OA (1) OA12348A (cs)
PA (1) PA8523101A1 (cs)
PE (1) PE20020385A1 (cs)
PL (1) PL359847A1 (cs)
PY (1) PY0117547A (cs)
SK (1) SK1082003A3 (cs)
SV (1) SV2002000574A (cs)
TN (1) TNSN01115A1 (cs)
UY (1) UY26861A1 (cs)
WO (1) WO2002009675A1 (cs)
ZA (1) ZA200300868B (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
AU2003294520A1 (en) * 2002-12-16 2004-07-09 Chx Technologies, Inc. Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
WO2006080481A1 (ja) * 2005-01-31 2006-08-03 Kyorin Pharmaceutical Co., Ltd. マルチプルユニット型経口徐放性製剤及びその製造方法
US11311490B2 (en) 2005-08-10 2022-04-26 Add Advanced Drug Delivery Technologies Ltd. Oral preparation with controlled release
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
CA2694440A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
BR112017004552A2 (pt) * 2014-09-09 2017-12-05 Charleston Laboratories Inc composições farmacêuticas
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
TNSN01115A1 (fr) 2005-11-10
OA12348A (en) 2004-03-19
EP1365748B1 (en) 2005-11-09
GT200100149A (es) 2002-06-25
KR20030024820A (ko) 2003-03-26
NO20030498L (no) 2003-01-31
DE60114887D1 (de) 2005-12-15
PY0117547A (es) 2003-11-03
PA8523101A1 (es) 2002-08-26
DE60114887T2 (de) 2006-07-20
SV2002000574A (es) 2002-12-02
HUP0301453A2 (hu) 2003-08-28
AP2001002233A0 (en) 2001-09-30
BG107361A (bg) 2003-06-30
EE200300051A (et) 2004-10-15
NZ522976A (en) 2004-11-26
ECSP034451A (es) 2003-03-10
ES2250429T3 (es) 2006-04-16
ZA200300868B (en) 2004-04-16
MXPA03000999A (es) 2003-06-09
HRP20030036A2 (en) 2003-04-30
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
CN1630511A (zh) 2005-06-22
AU2001270932A1 (en) 2002-02-13
CA2417887C (en) 2006-11-14
WO2002009675A9 (en) 2003-09-18
WO2002009675A1 (en) 2002-02-07
UY26861A1 (es) 2002-02-28
JP2004505034A (ja) 2004-02-19
AR030099A1 (es) 2003-08-13
PE20020385A1 (es) 2002-05-11
IS6649A (is) 2002-12-05
GB0018968D0 (en) 2000-09-20
EP1365748A2 (en) 2003-12-03
SK1082003A3 (en) 2004-09-08
ATE308978T1 (de) 2005-11-15
EA200300110A1 (ru) 2003-06-26
NO20030498D0 (no) 2003-01-31
CZ2003241A3 (cs) 2004-02-18
MA26934A1 (fr) 2004-12-20
PL359847A1 (pl) 2004-09-06
US20020034545A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU6317001A (en) Spontaneous pattern formation of functional materials
IL145581A0 (en) A modified release pharmaceutical composition comprising amoxycillin
GB2384747B (en) Bond pattern
MXPA03000999A (es) Composicion de electriptan en forma de particulas que muestrea un curso sigmoideo de liberacion controlada.
AU9701101A (en) Methylphenidate modified release formulations
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
AU3977099A (en) Controlled release oral dosage form
HUP0302244A3 (en) Modified inorganic particles
SG99955A1 (en) Artificial stone and formation therefor
GB0007842D0 (en) Sigma receptor ligands and their medical uses
SG84623A1 (en) Controlled release compositions
IL138192A0 (en) Controlled release oral dosage forms
AR028434A1 (es) Catalizador blanqueador y composicion y metodo para blanquear un sustrato
EP1335708A4 (en) METFORMIN COMPOSITIONS WITH CONTROLLED RELEASE
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
EP1283701A4 (en) A COATING COMPOSITION TO EASIER CONTROLLED RELEASE
SG86379A1 (en) Resist pattern formation method
PL354075A1 (en) Oral controlled release formulations
GB0015016D0 (en) Biotin-binding materials
IL160371A0 (en) A new extended release oral dosage form
AU143886S (en) A brick
GB0131027D0 (en) A durable waste form
HUP0401587A3 (en) A new extended release oral dosage form
GB2362852B (en) Photo-media printing using a white backing layer
AU144228S (en) A set of pavers